In adults with heart failure, tirzepatide lowers the chance of being hospitalized for heart failure by 53% compared to a placebo.
Strongly supported
Multiple high-quality studies back this claim.
Not medical advice. For informational purposes only. Always consult a healthcare professional.
In adults with heart failure, tirzepatide lowers the chance of being hospitalized for heart failure by 53% compared to a placebo.
See the technical phrasing
Tirzepatide reduces the relative risk of heart failure hospitalization by 53% compared to placebo in adults with heart failure, with a relative risk of 0.47 and a 95% confidence interval of 0.23–0.93.
Tirzepatide activates two receptors in the heart and fat tissue, which makes the heart use fuel more efficiently and reduces fluid buildup and strain on the heart muscle, lowering the chance of heart failure worsening to the point of hospitalization.
What the research says
Supports
1 study
Study: Abstract 4368175: GLP-1 Analogues and Cardiovascular Outcomes in Heart Failure Patients: A Network Meta-Analysis
In people with heart failure, tirzepatide cut hospital visits for heart failure by more than half compared to a placebo, and it worked better than other similar drugs tested. This makes it the top choice among these medicines for preventing heart failure hospitalizations.
Contradicts
0 studies
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies